Multiple biological activities of lactic acid in cancer: Influences on tumor growth, angiogenesis and metastasis

Current Pharmaceutical Design

Volumn 18, Issue 10, 2012, Pages 1319-1330

  Dhup, Suveera ^a   Dadhich, Rajesh Kumar ^a   Porporato, Paolo Ettore ^a   Sonveaux, Pierre ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Hypoxia; Hypoxia inducible factor 1; Lactate; Lactic acidosis; Monocarboxylate transporters; Nuclear factor kb; Tumor metabolism; Warburg effect

Indexed keywords

CD147 ANTIGEN; LACTIC ACID; MATRIX METALLOPROTEINASE; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL DEATH; COLON CANCER; DRUG ACTIVITY; ENDOMETRIUM CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GLYCOLYSIS; HUMAN; IN VIVO STUDY; KIDNEY CANCER; LACTIC ACIDOSIS; METASTASIS; MITOCHONDRION; NEOPLASM; OXIDATION REDUCTION POTENTIAL; OXYGEN CONSUMPTION; PHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CANCER; TUMOR XENOGRAFT; WOUND HEALING;

EID: 84857716739     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504902     Document Type: Article

References (166)

1. Thangaraju M, Gopal E, Martin PM, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 2006; 66: 11560-111564.
2. Thangaraju M, Carswell KN, Prasad PD, Ganapathy V. Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 2009; 417: 379-389.
3. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium trans-porter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 2003; 100: 8412-8417.
4. Sonveaux P, Vegran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008; 118: 3930-3942.
5. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
6. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mito-chondrial oxygen consumption. Cell Metab 2006; 3: 187-197.
7. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-19350.
8. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000; 350 Pt 1: 219-227.
9. Porporato PE, Dadhich RK, Dhup S, Copetti T, Sonveaux P. Anti-cancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2: 49.
10. Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 2004; 14: 267-274.
11. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8: 519-30.
12. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-899.
13. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42: 1S-93S.
14. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11: 2785-2808.
15. Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W. Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 1995; 55: 4757-4759.
16. Walenta S, Salameh A, Lyng H, et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 1997; 150: 409-415.
17. Walenta S, Wetterling M, Lehrke M, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000; 60: 916-921.
18. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51: 349-353.
19. Walenta S, Chau TV, Schroeder T, et al. Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists? J Cancer Res Clin Oncol 2003; 129: 321-326.
20. Hossmann KA, Mies G, Paschen W, Szabo L, Dolan E, Wechsler W. Regional metabolism of experimental brain tumors. Acta Neu-ropathol 1986; 69: 139-147.
21. Paschen W, Djuricic B, Mies G, Schmidt-Kastner R, Linn F. Lac-tate and pH in the brain: association and dissociation in different pathophysiological states. J Neurochem 1987; 48: 154-159.
22. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185: 675-686.
23. Yokota H, Guo J, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J Magn Reson Imaging 2007; 25: 992-929.
24. Gladden LB. Lactate metabolism: a new paradigm for the third millennium. J Physiol 2004; 558: 5-30.
25. Cori CF, Cori GT. Glycogen formation in the liver with d- and l-lactic acid. J Biol Chem 1929; 81: 389-403.
26. Brooks GA. Intra- and extra-cellular lactate shuttles. Med Sci Sports Exerc 2000; 32: 790-799.
27. Gladden LB. Lactic acid: New roles in a new millennium. Proc Natl Acad Sci USA 2001; 98: 395-397.
28. Pellerin L. Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem Int 2003; 43: 331-338.
29. Semenza GL. Tumor metabolism: cancer cells give and take lac-tate. J Clin Invest 2008; 118: 3835-3837.
30. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 2009; 92: 329-333.
31. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate fuel tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010; 9: 3506-3514.
32. Martinez-Outschoorn UE, Pavlides S, Howell A, et al. Stromal-epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol 2011; 43: 1045-1051.
33. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial lactate shuttle in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibro-blasts. Cell Cycle 2011; 10: 1772-1783.
34. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogene-sis. J Biol Chem 2002; 277: 23111-23115.
35. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J Biol Chem 2005; 280: 41928-41939.
36. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor an-giogenesis. Cancer Res 2011; 71: 2550-2560.
37. Trabold O, Wagner S, Wicke C, et al. Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. Wound Repair Regen 2003; 11: 504-509.
38. Beckert S, Farrahi F, Aslam RS, et al. Lactate stimulates endothe-lial cell migration. Wound Repair Regen 2006; 14: 321-324.
39. Hunt TK, Aslam R, Hussain Z, Beckert S. Lactate, with oxygen, incites angiogenesis. Adv Exp Med Biol 2008; 614: 73-80.
40. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999; 343 Pt 2: 281-299.
41. Garcia CK, Brown MS, Pathak RK, Goldstein JL. cDNA cloning of MCT2, a second monocarboxylate transporter expressed in different cells than MCT1. J Biol Chem 1995; 270: 1843-9.
42. Philp NJ, Yoon H, Lombardi L. Mouse MCT3 gene is expressed preferentially in retinal pigment and choroid plexus epithelia. Am J Physiol Cell Physiol 2001; 280: C1319-C1326.
43. Pellerin L, Bergersen LH, Halestrap AP, Pierre K. Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res 2005; 79: 55-64.
44. Deuticke B. Monocarboxylate transport in erythrocytes. J Membr Biol 1982; 70: 89-103.
45. Murray CM, Hutchinson R, Bantick JR, et al. Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat Chem Biol 2005; 1: 371-376.
46. Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010; 2010: 427694.
47. McCullagh KJ, Poole RC, Halestrap AP, O'Brien M, Bonen A. Role of the lactate transporter (MCT1) in skeletal muscles. Am J Physiol 1996; 271: E143-E150.
48. Halestrap AP, Meredith D. The SLC16 gene family-from monocar-boxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch 2004; 447: 619-628.
49. Morris ME, Felmlee MA. Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J 2008; 10: 311-321.
50. Mathupala SP, Parajuli P, Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycoly-sis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 2004; 55: 1410-1419.
51. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Oph-thalmol Vis Sci 2003; 44: 1305-1311.
52. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci USA 2005; 102: 16245-16250.
53. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007; 67: 4182-4189.
54. Slomiany MG, Grass GD, Robertson AD, et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 2009; 69: 1293-1301.
55. Chiche J, Fur YL, Vilmen C, et al. In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: Key role of the monocarboxylate transporter, MCT4, for inducing an alkaline in-tracellular pH. Int J Cancer 2011.
56. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006; 281: 9030-9037.
57. Dubouchaud H, Butterfield GE, Wolfel EE, Bergman BC, Brooks GA. Endurance training, expression, and physiology of LDH, MCT1, and MCT4 in human skeletal muscle. Am J Physiol Endo-crinol Metab 2000; 278: E571-E579.
58. Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lac-tate sensitive transcription factor network in L6 cells: activation of MCT1 and mitochondrial biogenesis. FASEB J 2007; 21: 2602-2612.
59. Asada K, Miyamoto K, Fukutomi T, et al. Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. Oncology 2003; 64: 380-388.
60. Ellis SM, Nabeshima K, Biswas C. Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor. Cancer Res 1989; 49: 3385-3391.
61. Ishibashi Y, Matsumoto T, Niwa M, et al. CD147 and matrix met-alloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004; 101: 1994-2000.
62. Ueda K, Yamada K, Urashima M, et al. Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol Rep 2007; 17: 731-735.
63. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycopro-tein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005; 93: 199-204.
64. Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-439.
65. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002; 99: 520-528.
66. Chen X, Lin J, Kanekura T, et al. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metas-tatic activity of malignant melanoma. Cancer Res 2006; 66: 11323-11330.
67. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008; 19: 52-60.
68. Tang Y, Nakada MT, Rafferty P, et al. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 2006; 4: 371-377.
69. Miyauchi S, Gopal E, Fei YJ, Ganapathy V. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids. J Biol Chem 2004; 279: 13293-13296.
70. Gopal E, Fei YJ, Sugawara M, et al. Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate. J Biol Chem 2004; 279: 44522-44532.
71. Ganapathy V, Thangaraju M, Gopal E, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 2008; 10: 193-199.
72. Bonen A. The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur J Appl Physiol 2001; 86: 6-11.
73. Bonen A, McCullagh KJ, Putman CT, Hultman E, Jones NL, Hei-genhauser GJ. Short-term training increases human muscle MCT1 and femoral venous lactate in relation to muscle lactate. Am J Physiol 1998; 274: E102-E107.
74. Fishbein WN. Lactate transporter defect: a new disease of muscle. Science 1986; 234: 1254-1256.
75. Bouzier-Sore AK, Voisin P, Canioni P, Magistretti PJ, Pellerin L. Lactate is a preferential oxidative energy substrate over glucose for neurons in culture. J Cereb Blood Flow Metab 2003; 23: 1298-1306.
76. Pellerin L, Magistretti PJ. Neuroenergetics: calling upon astrocytes to satisfy hungry neurons. Neuroscientist 2004; 10: 53-62.
77. Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA. Lactate: a preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab 2003; 23: 658-664.
78. Waagepetersen HS, Sonnewald U, Larsson OM, Schousboe A. A possible role of alanine for ammonia transfer between astrocytes and glutamatergic neurons. J Neurochem 2000; 75: 471-479.
79. Busk M, Walenta S, Mueller-Klieser W, et al. Inhibition of tumor lactate oxidation: Consequences for the tumor microenvironment. Radiother Oncol 2011; 99: 404-411.
80. Bueno V, Binet I, Steger U, et al. The specific monocarboxylate transporter (MCT1) inhibitor, AR-C117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation 2007; 84: 1204-1207.
81. Ekberg H, Qi Z, Pahlman C, et al. The specific monocarboxylate transporter-1 (MCT-1) inhibitor, AR-C117977, induces donor-specific suppression, reducing acute and chronic allograft rejection in the rat. Transplantation 2007; 84: 1191-1199.
82. Curi R, Newsholme P, Newsholme EA. Metabolism of pyruvate by isolated rat mesenteric lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. Biochem J 1988; 250: 383-388.
83. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000; 6: 15-19.
84. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16: 430-450.
85. Bergmeyer HU, Bernt E. In: Bergmeyer HU, Ed. Methods of Enzymatic Analysis. Deerfield Beach: Verlag-Chemie. 1974; pp. 574-579.
86. Andres V, Carreras J, Cusso R. Regulation of muscle phosphofruc-tokinase by physiological concentrations of bisphosphorylated hexoses: effect of alkalinization. Biochem Biophys Res Commun 1990; 172: 328-334.
87. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002; 8: 1284-1291.
88. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26: 299-310.
89. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-181.
90. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449-6465.
91. Newell K, Franchi A, Pouyssegur J, Tannock I. Studies with glyco-lysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 1993; 90: 1127-1131.
92. Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998; 77: 1726-1731.
93. Gullino PM, Grantham FH, Smith SH, Haggerty AC. Modifications of the acid-base status of the internal milieu of tumors. J Natl Cancer Inst 1965; 34: 857-869.
94. Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011; 226: 299-308.
95. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005; 5: 786-795.
96. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006; 66: 5216-5223.
97. Park HJ, Lyons JC, Ohtsubo T, Song CW. Acidic environment causes apoptosis by increasing caspase activity. Br J Cancer 1999; 80: 1892-1897.
98. Williams AC, Collard TJ, Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 1999; 18: 3199-3204.
99. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acido-sis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999; 5: 3711-3721.
100. Shi Q, Le X, Wang B, et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Onco-gene 2001; 20: 3751-6.
101. Sloane BF, Moin K, Krepela E, Rozhin J. Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev 1990; 9: 333-352.
102. Rozhin J, Sameni M, Ziegler G, Sloane BF. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994; 54: 6517-6525.
103. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol 2001; 69: 522-530.
104. Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ. Metabolic changes during carcinogenesis: potential impact on inva-siveness. J Theor Biol 2007; 244: 703-713.
105. Holman CM, Kan CC, Gehring MR, Van Wart HE. Role of His-224 in the anomalous pH dependence of human stromelysin-1. Biochemistry 1999; 38: 677-681.
106. Kato Y, Ozawa S, Tsukuda M, et al. Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metallo-proteinase-9 expression in mouse metastatic melanoma. FEBS J 2007; 274: 3171-3183.
107. Kindzelskii AL, Amhad I, Keller D, et al. Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator. Histochem Cell Biol 2004; 121: 299-310.
108. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res 2001; 61: 3493-3500.
109. Tedone T, Correale M, Barbarossa G, Casavola V, Paradiso A, Reshkin SJ. Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J 1997; 11: 785-792.
110. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006; 6: 764-775.
111. Izumi H, Takahashi M, Uramoto H, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011; 102: 1007-1013.
112. Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Muel-ler-Klieser W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 2011; 39: 453-463.
113. Stern R, Shuster S, Neudecker BA, Formby B. Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 2002; 276: 24-31.
114. Rudrabhatla SR, Mahaffey CL, Mummert ME. Tumor microenvi-ronment modulates hyaluronan expression: the lactate effect. J Invest Dermatol 2006; 126: 1378-1387.
115. Formby B, Stern R. Lactate-sensitive response elements in genes involved in hyaluronan catabolism. Biochem Biophys Res Com-mun 2003; 305: 203-208.
116. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-539.
117. Baumann F, Leukel P, Doerfelt A, et al. Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metallo-proteinase-2. Neuro Oncol 2009; 11: 368-380.
118. Wick W, Naumann U, Weller M. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 2006; 12: 341-349.
119. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
120. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27: 7381-7393.
121. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006; 91: 807-819.
122. Markert CL, Shaklee JB, Whitt GS. Evolution of a gene. Multiple genes for LDH isozymes provide a model of the evolution of gene structure, function and regulation. Science 1975; 189: 102-114.
123. Leiblich A, Cross SS, Catto JW, et al. Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene 2006; 25: 2953-2960.
124. Tanaka M, Nakamura F, Mizokawa S, et al. Role of lactate in the brain energy metabolism: revealed by Bioradiography. Neurosci Res 2004; 48: 13-20.
125. Leite TC, Coelho RG, Da Silva D, Coelho WS, Marinho-Carvalho MM, Sola-Penna M. Lactate downregulates the glycolytic enzymes hexokinase and phosphofructokinase in diverse tissues from mice. FEBS Lett 2011; 585: 92-98.
126. Elser M, Borsig L, Hassa PO, et al. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol Cancer Res 2008; 6: 282-290.
127. Dioum EM, Chen R, Alexander MS, et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacety-lase sirtuin 1. Science 2009; 324: 1289-1293.
128. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271-275.
129. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 2001; 20: 5197-5206.
130. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001; 98: 9630-9635.
131. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 2003; 22: 4082-4090.
132. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003; 278: 30772-30780.
133. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-684.
134. Hewitson KS, Lienard BM, McDonough MA, et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 2007; 282: 3293-3301.
135. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha pro-lyl hydroxylase. Cancer Cell 2005; 7: 77-85.
136. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8: 143-153.
137. Koivunen P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hy-droxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007; 282: 4524-4532.
138. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxy-genases. Cancer Cell 2011; 19: 17-30.
139. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-2239.
140. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265.
141. Samuvel DJ, Sundararaj KP, Nareika A, Lopes-Virella MF, Huang Y. Lactate boosts TLR4 signaling and NF-kappaB pathway-mediated gene transcription in macrophages via monocarboxylate transporters and MD-2 up-regulation. J Immunol 2009; 182: 2476-2484.
142. Cummins EP, Berra E, Comerford KM, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hy-poxia-induced NFkappaB activity. Proc Natl Acad Sci USA 2006; 103: 18154-18159.
143. Ahmed S, Tsuchiya T. Novel mechanism of tumorigenesis: increased transforming growth factor-beta 1 suppresses the expression of connexin 43 in BALB/cJ mice after implantation of poly-L-lactic acid. J Biomed Mater Res A 2004; 70: 335-340.
144. Shime H, Yabu M, Akazawa T, et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 2008; 180: 7175-7183.
145. Yabu M, Shime H, Hara H, et al. IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. Int Immunol 2011; 23: 29-41.
146. Chang HY, Sneddon JB, Alizadeh AA, et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004; 2: E7.
147. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
148. Hunt TK, Pai MP. The effect of varying ambient oxygen tensions on wound metabolism and collagen synthesis. Surg Gynecol Obstet 1972; 135: 561-567.
149. Hunt TK, Conolly WB, Aronson SB, Goldstein P. Anaerobic metabolism and wound healing: an hypothesis for the initiation and cessation of collagen synthesis in wounds. Am J Surg 1978; 135: 328-332.
150. Ghani QP, Wagner S, Hussain MZ. Role of ADP-ribosylation in wound repair. The contributions of Thomas K. Hunt, MD. Wound Repair Regen 2003; 11: 439-444.
151. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008; 453: 314-321.
152. Constant JS, Feng JJ, Zabel DD, et al. Lactate elicits vascular en-dothelial growth factor from macrophages: a possible alternative to hypoxia. Wound Repair Regen 2000; 8: 353-360.
153. Hunt TK, Aslam RS, Beckert S, et al. Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal 2007; 9: 1115-1124.
154. Milovanova TN, Bhopale VM, Sorokina EM, et al. Lactate stimulates vasculogenic stem cells via the thioredoxin system and engages an autocrine activation loop involving hypoxia-inducible factor 1. Mol Cell Biol 2008; 28: 6248-6261.
155. Wagner S, Hussain MZ, Hunt TK, Bacic B, Becker HD. Stimulation of fibroblast proliferation by lactate-mediated oxidants. Wound Repair Regen 2004; 12: 368-373.
156. Kelly BD, Hackett SF, Hirota K, et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angi-ogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93: 1074-1081.
157. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
158. Kraus WL, Lis JT. PARP goes transcription. Cell 2003; 113: 677-683.
159. Ahel I, Ahel D, Matsusaka T, et al. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 2008; 451: 81-85.
160. Wagner S, Hussain MZ, Beckert S, et al. Lactate down-regulates cellular poly(ADP-ribose) formation in cultured human skin fibro-blasts. Eur J Clin Invest 2007; 37: 134-139.
161. Kumar VB, Viji RI, Kiran MS, Sudhakaran PR. Endothelial cell response to lactate: implication of PAR modification of VEGF. J Cell Physiol 2007; 211: 477-485.
162. Zabel DD, Feng JJ, Scheuenstuhl H, Hunt TK, Hussain MZ. Lac-tate stimulation of macrophage-derived angiogenic activity is associated with inhibition of Poly(ADP-ribose) synthesis. Lab Invest 1996; 74: 644-649.
163. Hussain MZ, Ghani QP, Hunt TK. Inhibition of prolyl hydroxylase by poly(ADP-ribose) and phosphoribosyl-AMP. Possible role of ADP-ribosylation in intracellular prolyl hydroxylase regulation. J Biol Chem 1989; 264: 7850-7855.
164. Cai TQ, Ren N, Jin L, et al. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun 2008; 377: 987-991.
165. Liu C, Wu J, Zhu J, et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J Biol Chem 2009; 284: 2811-2822.
166. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010; 6: 127-148.